Program
HU6
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Overweight · Heart Failure · Diabetes Mellitus, Type 2, led by Rivus Pharmaceuticals.
Furthest: phase 2, since May 2, 20218 company-led studies, 2 open or runningNext primary completion: Feb 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Rivus Pharmaceuticals | 82 open or running | phase 2since May 2, 2021 | Jul 3, 2020 | Feb 2027phase 2 · NCT07491458 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 3, 2020First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT04463017 · 64 enrolled · United States
- Jan 8, 2021Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT04709913 · 30 enrolled · United States
- May 2, 2021Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT04874233 · 80 enrolled · United States
- Mar 9, 2022Phase 2 study in Heart Failure With Preserved Ejection FractionNCT05284617 · 67 enrolled · United States
- Jul 31, 2023Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT05979779 · 219 enrolled · United States
- Oct 11, 2023Phase 2 study in Diabetes Mellitus, Type 2NCT06104358 · United States
- Sep 5, 2025Phase 1 study in OverweightNCT07170189 · 59 enrolled · United States
- Mar 2, 2026Phase 2 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNCT07491458 · 180 planned · United States
Ahead
- Feb 2027Primary completion: phase 2 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNCT07491458
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07491458MASH - Metabolic Dysfunction-Associated Steatohepatitis · United States | 2 | Recruiting | Feb 2027 | 180 |
| NCT07170189Overweight · United States | 1 | Completed | Dec 4, 2025 | 59 |
| NCT06104358Diabetes Mellitus, Type 2 · United States | 2 | Withdrawn | Feb 2025 | 0 |
| NCT05979779Non-alcoholic Fatty Liver Disease · United States | 2 | Active, not recruiting | Jan 21, 2025 | 219 |
| NCT05284617Heart Failure With Preserved Ejection Fraction · United States | 2 | Completed | May 24, 2024 | 67 |
| NCT04874233Non-alcoholic Fatty Liver Disease · United States | 2 | Completed | Nov 30, 2021 | 80 |
| NCT04709913Non-alcoholic Fatty Liver Disease · United States | 1 | Completed | Apr 30, 2021 | 30 |
| NCT04463017Non-alcoholic Fatty Liver Disease · United States | 1 | Completed | Mar 30, 2021 | 64 |
How it is read
Names in the registry
- “HU6”, 8 entries
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 4 studies
- Fatty Liver, 1 study
- Overweight, 1 study
- Heart Failure, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.